MAM
MDGL icon

Meeder Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Meeder Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17
Closed -$8.9K – 1003
2026
Q1 		$8.9K Buy
17
+10
+143% +$4.78K ﹤0.01% 720
2025
Q4 		$4.08K Hold
7
– – ﹤0.01% 820
2025
Q3 		$3.21K Buy
+7
New +$2.61K ﹤0.01% 737
2025
Q2 		– Sell
-5
Closed -$1.66K – 949
2025
Q1 		$1.66K Sell
5
-2
-29% -$657 ﹤0.01% 877
2024
Q4 		$2.16K Buy
+7
New +$1.97K ﹤0.01% 886
2024
Q2 		– Sell
-10
Closed -$2.67K – 938
2024
Q1 		$2.67K Buy
+10
New +$2.36K ﹤0.01% 703
2021
Q3 		– Sell
-3,364
Closed -$328K – 2575
2021
Q2 		$328K Buy
+3,364
New +$398K 0.02% 621
2019
Q1 		– Sell
-557
Closed -$63K – 1790
2018
Q4 		$63K Sell
557
-5
-0.9% -$774 0.01% 752
2018
Q3 		$120K Buy
562
+126
+29% +$31.6K 0.01% 607
2018
Q2 		$122K Buy
436
+326
+296% +$57.2K 0.01% 591
2018
Q1 		$13K Buy
110
+3
+3% +$370 ﹤0.01% 1000
2017
Q4 		$10K Buy
107
+90
+529% +$5.14K ﹤0.01% 1126
2017
Q3 		$1K Buy
+17
New +$318 ﹤0.01% 1553

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Meeder Asset Management's MDGL Position: Q2 2026 in Review

Meeder Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 17 shares — an estimated $8.9K sold.

Meeder Asset Management first reported a position in MDGL in Q3 2017 and held it in 13 quarters. The position peaked at $328K in Q2 2021. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Meeder Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Meeder Asset Management sold 17 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $8.9K.
  • Meeder Asset Management first reported a position in Madrigal Pharmaceuticals in Q3 2017 and held it in 13 quarters.
  • Meeder Asset Management's Madrigal Pharmaceuticals position peaked at $328K in Q2 2021.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.